Crescent Biopharma Advances Oncology Pipeline with Key Clinical Trials and Data Readouts on Horizon — Crescent Biopharma, Inc.

Event summary

CR-001 Phase 1/2 ASCEND trial ongoing in multiple solid tumor types, with first ADC combination trial expected to initiate in H2 2026.
CR-003 Phase 1/2 trial ongoing in China, with proof-of-concept data anticipated in Q1 2027.
CR-002 IND application submission planned for mid-2026, with clinical trial initiation expected in H2 2026.
Cash position of $189.2 million as of March 31, 2026, anticipated to fund operations into 2028.

The big picture

Crescent Biopharma is positioning itself as a key player in the next wave of oncology therapies, leveraging bispecific antibodies and ADCs. The company's strategic partnership with Kelun-Biotech underscores its focus on global expansion, particularly in the lucrative Chinese market. With multiple clinical data readouts anticipated beginning in Q1 2027, Crescent Biopharma is poised to compete with established players in the immuno-oncology space.

What we're watching

Clinical Execution: The pace at which Crescent Biopharma can deliver proof-of-concept data for CR-001, CR-002, and CR-003 will determine the company's valuation and investor confidence.
Partnership Dynamics: Whether the strategic collaboration with Kelun-Biotech can accelerate regulatory approvals and commercialization in Greater China.
Financial Runway: How Crescent Biopharma manages its cash position to support operations into 2028 while advancing multiple clinical trials.